Health-related social needs in HF, removing age from frailty scores, CIED concerns about smartwatches, and more.

In 2025, cardiology delved deeper into sex-specific risk factors and how to leverage them in prevention, Stacey Rosen says.

As research continues into how AI will impact practice, there are open questions about medical training, regulation, and more ...

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

The prospective data indicate that clinicians should be aggressive with lipid-lowering therapies in these patients, experts say.

After today, andexanet alfa (Andexxa; AstraZeneca) will no longer be made or sold in the United States, according to an alert from the US Food and Drug Administration.

The drug was as good as a proven GLP-1, giving doctors another potent option for patients with type 2 diabetes and ...

By improving BP control and treatment adherence, use of fixed-dose combination therapies is expected to drive down CV events ...

Gaxiola López shaped the field of interventional cardiology, with colleagues saying he’ll be remembered as a “visionary.” ...

Office and ambulatory BP improved, with minimal side effects, although some say edema needs to be watched carefully.

Achieving remission from prediabetes appears to substantially lower the risk of cardiovascular death or hospitalization for heart failure decades later, according to global registry data.

Echocardiograms reveal a rapid rise in LV hypertrophy from ages 17 to 24 years, bolstering the case for primordial prevention.